108 related articles for article (PubMed ID: 25679319)
1. Deciphering the impact of somatic mutations in exon 20 and exon 9 of PIK3CA gene in breast tumors among Indian women through molecular dynamics approach.
Sudhakar N; Priya Doss CG; Thirumal Kumar D; Chakraborty C; Anand K; Suresh M
J Biomol Struct Dyn; 2016; 34(1):29-41. PubMed ID: 25679319
[TBL] [Abstract][Full Text] [Related]
2. Detection of PIK3CA gene mutations with HRM analysis and association with IGFBP-5 expression levels in breast cancer.
Dirican E; Kaya Z; Gullu G; Peker I; Ozmen T; Gulluoglu BM; Kaya H; Ozer A; Akkiprik M
Asian Pac J Cancer Prev; 2014; 15(21):9327-33. PubMed ID: 25422220
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of PIK3CA mutations as a biomarker in Chinese breast carcinomas from Western China.
Cheng J; Fu S; Wei C; Tania M; Khan MA; Imani S; Zhou B; Chen H; Xiao X; Wu J; Fu J
Cancer Biomark; 2017; 19(1):85-92. PubMed ID: 28269754
[TBL] [Abstract][Full Text] [Related]
4. Molecular evaluation of PIK3CA gene mutation in breast cancer: determination of frequency, distribution pattern and its association with clinicopathological findings in Indian patients.
Ahmad F; Badwe A; Verma G; Bhatia S; Das BR
Med Oncol; 2016 Jul; 33(7):74. PubMed ID: 27282497
[TBL] [Abstract][Full Text] [Related]
5. PIK3CA mutations in Peruvian patients with HER2-amplified and triple negative non-metastatic breast cancers.
Castaneda CA; Lopez-Ilasaca M; Pinto JA; Chirinos-Arias M; Doimi F; Neciosup SP; Rojas KI; Vidaurre T; Balko JM; Arteaga CL; Gomez HL
Hematol Oncol Stem Cell Ther; 2014 Dec; 7(4):142-8. PubMed ID: 25467032
[TBL] [Abstract][Full Text] [Related]
6. Association between the Prevalence of Somatic Mutations in PIK3CA Gene in Tumors and Clinical and Morphological Characteristics of Breast Cancer Patients.
Filipenko ML; Os'kina NA; Oskorbin IA; Mishukova OV; Ovchinnikova LK; Gershtein ES; Kushlinskii NE
Bull Exp Biol Med; 2017 Jun; 163(2):250-254. PubMed ID: 28726194
[TBL] [Abstract][Full Text] [Related]
7. Investigating the Inhibitory Effect of Wortmannin in the Hotspot Mutation at Codon 1047 of PIK3CA Kinase Domain: A Molecular Docking and Molecular Dynamics Approach.
Kumar DT; Doss CG
Adv Protein Chem Struct Biol; 2016; 102():267-97. PubMed ID: 26827608
[TBL] [Abstract][Full Text] [Related]
8. PIK3CA mutations in head and neck squamous cell carcinoma.
Qiu W; Schönleben F; Li X; Ho DJ; Close LG; Manolidis S; Bennett BP; Su GH
Clin Cancer Res; 2006 Mar; 12(5):1441-6. PubMed ID: 16533766
[TBL] [Abstract][Full Text] [Related]
9. Hotspot mutations in PIK3CA associate with first-line treatment outcome for aromatase inhibitors but not for tamoxifen.
Ramirez-Ardila DE; Helmijr JC; Look MP; Lurkin I; Ruigrok-Ritstier K; van Laere S; Dirix L; Sweep FC; Span PN; Linn SC; Foekens JA; Sleijfer S; Berns EM; Jansen MP
Breast Cancer Res Treat; 2013 May; 139(1):39-49. PubMed ID: 23592373
[TBL] [Abstract][Full Text] [Related]
10. Novel method for PIK3CA mutation analysis: locked nucleic acid--PCR sequencing.
Ang D; O'Gara R; Schilling A; Beadling C; Warrick A; Troxell ML; Corless CL
J Mol Diagn; 2013 May; 15(3):312-8. PubMed ID: 23541593
[TBL] [Abstract][Full Text] [Related]
11. [Screening for mutations in the hotspot mutation regions of PIK3CA gene in nasopharyngeal carcinoma].
Liu P; Li DJ; Qin HD; Zhang RH; Chen LZ; Zeng YX
Ai Zheng; 2007 Jan; 26(1):15-20. PubMed ID: 17222361
[TBL] [Abstract][Full Text] [Related]
12. Genetic alterations of the PIK3CA oncogene in human oral squamous cell carcinoma in an Indian population.
Shah S; Shah S; Padh H; Kalia K
Oral Surg Oral Med Oral Pathol Oral Radiol; 2015 Nov; 120(5):628-35. PubMed ID: 26453385
[TBL] [Abstract][Full Text] [Related]
13. Analysis of PIK3CA exon 9 and 20 mutations in breast cancers using PCR-HRM and PCR-ARMS: correlation with clinicopathological criteria.
Harlé A; Lion M; Lozano N; Husson M; Harter V; Genin P; Merlin JL
Oncol Rep; 2013 Mar; 29(3):1043-52. PubMed ID: 23314198
[TBL] [Abstract][Full Text] [Related]
14. Detection of TP53/PIK3CA Mutations in Cell-Free Plasma DNA From Metastatic Breast Cancer Patients Using Next Generation Sequencing.
Nakauchi C; Kagara N; Shimazu K; Shimomura A; Naoi Y; Shimoda M; Kim SJ; Noguchi S
Clin Breast Cancer; 2016 Oct; 16(5):418-423. PubMed ID: 27265061
[TBL] [Abstract][Full Text] [Related]
15. Different prognostic roles of mutations in the helical and kinase domains of the PIK3CA gene in breast carcinomas.
Barbareschi M; Buttitta F; Felicioni L; Cotrupi S; Barassi F; Del Grammastro M; Ferro A; Dalla Palma P; Galligioni E; Marchetti A
Clin Cancer Res; 2007 Oct; 13(20):6064-9. PubMed ID: 17947469
[TBL] [Abstract][Full Text] [Related]
16. PIK3CA exon 20 mutations are associated with poor prognosis in breast cancer patients.
Mangone FR; Bobrovnitchaia IG; Salaorni S; Manuli E; Nagai MA
Clinics (Sao Paulo); 2012 Nov; 67(11):1285-90. PubMed ID: 23184205
[TBL] [Abstract][Full Text] [Related]
17. PIK3CA mutations mostly begin to develop in ductal carcinoma of the breast.
Li H; Zhu R; Wang L; Zhu T; Li Q; Chen Q; Wang H; Zhu H
Exp Mol Pathol; 2010 Feb; 88(1):150-5. PubMed ID: 19818761
[TBL] [Abstract][Full Text] [Related]
18. PIK3CA gene mutations in breast carcinoma in Malaysian patients.
Ching-Shian Leong V; Jabal MF; Leong PP; Abdullah MA; Gul YA; Seow HF
Cancer Genet Cytogenet; 2008 Dec; 187(2):74-9. PubMed ID: 19027487
[TBL] [Abstract][Full Text] [Related]
19. PIK3CA mutations are associated with lower rates of pathologic complete response to anti-human epidermal growth factor receptor 2 (her2) therapy in primary HER2-overexpressing breast cancer.
Loibl S; von Minckwitz G; Schneeweiss A; Paepke S; Lehmann A; Rezai M; Zahm DM; Sinn P; Khandan F; Eidtmann H; Dohnal K; Heinrichs C; Huober J; Pfitzner B; Fasching PA; Andre F; Lindner JL; Sotiriou C; Dykgers A; Guo S; Gade S; Nekljudova V; Loi S; Untch M; Denkert C
J Clin Oncol; 2014 Oct; 32(29):3212-20. PubMed ID: 25199759
[TBL] [Abstract][Full Text] [Related]
20. PIK3CA mutations in non-small cell lung cancer (NSCLC): genetic heterogeneity, prognostic impact and incidence of prior malignancies.
Scheffler M; Bos M; Gardizi M; König K; Michels S; Fassunke J; Heydt C; Künstlinger H; Ihle M; Ueckeroth F; Albus K; Serke M; Gerigk U; Schulte W; Töpelt K; Nogova L; Zander T; Engel-Riedel W; Stoelben E; Ko YD; Randerath W; Kaminsky B; Panse J; Becker C; Hellmich M; Merkelbach-Bruse S; Heukamp LC; Büttner R; Wolf J
Oncotarget; 2015 Jan; 6(2):1315-26. PubMed ID: 25473901
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]